Journal article · 2026 · Open access
Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases
Shengming kexue, 38(4), 645–650 · Published 1 April 2026 · DOI 10.3724/cbls.2026079
In brief
“Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases” is a 2026 journal article by Chen-Xing ZHANG and 2 co-authors, published in Shengming kexue. OpenAlex counts 0 citations as of 19 November 2026. It is open access: the full text is free to read at Shengming kexue.
- Citations
- 0
- References
- 40
- Authors
- 3
Abstract
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a transformative immunotherapeutic strategy with groundbreaking success in B-cell malignancies. In recent years, this powerful approach has been rapidly extended to autoimmune diseases, where autoreactive B cells play a central pathogenic role by producing autoantibodies, presenting autoantigens, and promoting chronic inflammation. Conventional treatments, including immunosuppressants and B-cell-depleting antibodies, often fail to induce sustained remission in refractory cases due to incomplete elimination of pathological B cells in lymphoid organs and inflamed tissues. This review comprehensively summarizes the structural design, generational evolution, clinical workflow, safety profiles, recent advances, and remaining challenges of CAR-T therapy for autoimmune diseases. CAR-T cells are engineered to target B-cell-restricted antigens such as CD19, CD20, and CD22 in an MHC independent manner, enabling specific and efficient clearance of autoreactive B cells. To date, five generations of CAR constructs have been developed, and fifth-generation universal allogeneic CAR-T cells represent a major breakthrough by offering offtheshelf availability, reduced manufacturing time, and lower costs. The standard clinical pipeline encompasses patient eligibility assessment, apheresis, T-cell isolation and genetic modification, ex vivo expansion, lymphodepletion chemotherapy, CAR-T infusion, intensive monitoring for adverse events, efficacy evaluation, and long-term follow-up. The primary adverse reactions are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are mostly manageable with timely intervention. Promising clinical data have demonstrated that CD19-targeted CAR-T therapy can induce durable drug-free remission in refractory systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis. Nevertheless, several critical challenges persist, including impaired quantity and function of autologous T cells in heavily pretreated patients, potential amplification of autoreactive T-cell clones, high production costs, and insufficient long-term safety and efficacy data. Future investigations should focus on optimizing CAR structure, developing safer universal cell products, establishing standardized protocols, and conducting large-scale multi-center clinical trials to advance CAR-T therapy into a mainstream curative option for refractory autoimmune diseases.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
ZHANG, C.-X., YIN, L., & MAO, Y.-Y. (2026). Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases. Shengming kexue, 38(4), 645–650. https://doi.org/10.3724/cbls.2026079
MLA 9
ZHANG, Chen-Xing, et al. “Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases.” Shengming kexue, vol. 38, no. 4, 2026, pp. 645–650. https://doi.org/10.3724/cbls.2026079.
Chicago
ZHANG, Chen-Xing, Lei YIN, and You-Ying MAO. 2026. “Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases.” Shengming kexue 38 (4): 645–650. https://doi.org/10.3724/cbls.2026079.
Harvard
ZHANG, C.-X., YIN, L. and MAO, Y.-Y. (2026) ‘Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases’, Shengming kexue, 38(4), pp. 645–650. doi:10.3724/cbls.2026079.
IEEE
C.-X. ZHANG, L. YIN, and Y.-Y. MAO, “Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases,” Shengming kexue, vol. 38, no. 4, pp. 645–650, 2026, doi: 10.3724/cbls.2026079.
BibTeX
@article{zhang2026advances,
title = {{Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases}},
author = {ZHANG, Chen-Xing and YIN, Lei and MAO, You-Ying},
journal = {Shengming kexue},
year = {2026},
volume = {38},
number = {4},
pages = {645--650},
doi = {10.3724/cbls.2026079},
url = {https://doi.org/10.3724/cbls.2026079}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- CAR T-cell therapy
- autoimmune disease
- autoreactive B cells
- CD19
- CD20
- CD22
- cytokine release syndrome
- immune effector cell-associated neurotoxicity syndrome
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
ZHANG, C.-X., YIN, L., & MAO, Y.-Y. (2026). Advances of chimeric antigen receptor T cell (CAR-T) therapy for autoimmune diseases. Shengming kexue, 38(4), 645–650. https://doi.org/10.3724/cbls.2026079
How many times has this paper been cited?
0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Shengming kexue: sign in and open the PDF from this page.
Who wrote this paper?
Chen-Xing ZHANG, Lei YIN, You-Ying MAO.
What is the DOI of this paper?
10.3724/cbls.2026079, permanently at https://doi.org/10.3724/cbls.2026079. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.